Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 53

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 53
---
 capital for employee and advisory options. •“FOR” Proposal No. 6 to approve the conditional share capital for shareholders’ options. •“FOR” Proposal No. 7 to approve the transfer and voting rights limitation of 9.99%. •“FOR” Proposal No. 8 to approve the name change of NLS. •“FOR” Proposal No. 9 to approve the election of the new members to the NLS Board. •“FOR” Proposal No. 10 to approve the election of members of the Compensation, Nomination and Governance Committee. •“FOR” Proposal No. 11 to approve the composition of the new senior management following the Merger. •“FOR” Proposal No. 12.1 to approve the compensation for the members of the NLS Board. •“FOR” Proposal No. 12.2 to approve compensation for the executive officers. •“FOR” Proposal No. 13 to approve the CVR Agreement. •“FOR” Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Q.What interests do the current executive officers and directors of NLS and Kadimastem have in the Merger? In considering the recommendation of NLS Board to vote in favor of the Merger, shareholders should be aware that, aside from their interests as shareholders, certain NLS directors and executive officers have interests in the Merger that differ from, or extend beyond, those of NLS’s shareholders generally. NLS’s directors were aware of and considered these interests, among other matters, in evaluating the Merger and in recommending to shareholders that they approve the Merger. Shareholders should take these interests into account in deciding whether to approve the Merger. NLS’s directors and executive officers do not have interests in the Merger, except for the fact that: Mr.Alexander Zwyer will continue to be a director of the combined company after the Effective Time of the Merger. Mr.Eric Konofal will continue to be a part -timeofficer of the combined company after the Effective Time of the Merger. In addition, as of the Closing, NLS shall, at Kadimastem’s expense (up to a maximum of $200,000), obtain a “run -off” prepaid directors’ and officers’ liability insurance policy for the benefit of NLS’s current and former officers and directors, effective as of the Closing, with a reporting period of six (6) years after the